Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KDR overexpression
i
Other names:
KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor (a type III receptor tyrosine kinase)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3791
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KDR overexpression
Glioblastoma
KDR overexpression
Glioblastoma
bevacizumab + erlotinib
Resistant: C3 – Early Trials
bevacizumab + erlotinib
Resistant
:
C3
bevacizumab + erlotinib
Resistant: C3 – Early Trials
bevacizumab + erlotinib
Resistant
:
C3
KDR overexpression
Hepatocellular Cancer
KDR overexpression
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: C3 – Early Trials
bevacizumab + atezolizumab
Sensitive
:
C3
bevacizumab + atezolizumab
Sensitive: C3 – Early Trials
bevacizumab + atezolizumab
Sensitive
:
C3
KDR overexpression
Glioblastoma
KDR overexpression
Glioblastoma
bevacizumab
Resistant: C3 – Early Trials
bevacizumab
Resistant
:
C3
bevacizumab
Resistant: C3 – Early Trials
bevacizumab
Resistant
:
C3
KDR overexpression
Osteosarcoma
KDR overexpression
Osteosarcoma
anlotinib
Sensitive: C3 – Early Trials
anlotinib
Sensitive
:
C3
anlotinib
Sensitive: C3 – Early Trials
anlotinib
Sensitive
:
C3
KDR overexpression
Non Small Cell Lung Cancer
KDR overexpression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KDR overexpression
Non Small Cell Lung Cancer
KDR overexpression
Non Small Cell Lung Cancer
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
KDR overexpression
Nasopharyngeal Carcinoma
KDR overexpression
Nasopharyngeal Carcinoma
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
KDR overexpression
Breast Cancer
KDR overexpression
Breast Cancer
sunitinib
Sensitive: C4 – Case Studies
sunitinib
Sensitive
:
C4
sunitinib
Sensitive: C4 – Case Studies
sunitinib
Sensitive
:
C4
KDR overexpression
Renal Cell Carcinoma
KDR overexpression
Renal Cell Carcinoma
sunitinib
Sensitive: D – Preclinical
sunitinib
Sensitive
:
D
sunitinib
Sensitive: D – Preclinical
sunitinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login